| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H24N6O |
| Molecular Weight | 388.4656 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C(CN1CCCCC1)OC2=CC(=CC=C2)C3=NNC4=C3C=C(C=C4)C5=NNC=N5
InChI
InChIKey=XDJCLCLBSGGNKS-UHFFFAOYSA-N
InChI=1S/C22H24N6O/c1-2-9-28(10-3-1)11-12-29-18-6-4-5-16(13-18)21-19-14-17(22-23-15-24-27-22)7-8-20(19)25-26-21/h4-8,13-15H,1-3,9-12H2,(H,25,26)(H,23,24,27)
| Molecular Formula | C22H24N6O |
| Molecular Weight | 388.4656 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CC-401 is a potent inhibitor of all three forms of c-Jun N-terminal Kinase (JNK) (Ki of 25 to 50 nM) and has at least 40-fold selectivity for JNK compared with other related kinases. Celgene was developing CC 401 for the treatment of cancer and inflammatory disorders. CC 401 was being developed in an IV formulation and was in a phase I trial in patients with refractory acute myelogenous leukaemia. However, trials have ended and the company is not pursuing CC 401, but will advance other JNK inhibitors.
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
An earlier phase I trial of CC 401, initiated in October 2002, was completed and the drug was found to be safe and well tolerated in healthy volunteers over the range of IV doses studied (dosage is unknown).
CC-401 is prepared in a sodium citrate vehicle and administered to rats by twice-daily gavage at 100 mg/kg.
Route of Administration:
Other
